The Pharmacovigilance and Drug Safety Software Market Revenue was valued at USD 6.83 billion in 2022 and is projected to more than double, reaching USD 14.86 billion by 2030, with a robust CAGR of 10.2% over the forecast period from 2023 to 2030. The growing demand for effective monitoring, reporting, and managing adverse drug reactions (ADRs) drives the adoption of advanced pharmacovigilance an..